XML 22 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2022
Mar. 16, 2023
Jun. 30, 2022
Cover [Abstract]      
Document Type 10-K    
Document Period End Date Dec. 31, 2022    
Document Annual Report true    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-35890    
Entity Registrant Name Tempest Therapeutics, Inc.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 45-1472564    
Entity Address, Address Line One 2000 Sierra Point Parkway    
Entity Address, Address Line Two Suite 400    
Entity Address, City or Town Brisbane    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 94005    
City Area Code (415)    
Local Phone Number 798-8589    
Title of 12(b) Security Common Stock, $0.001 par value    
Trading Symbol TPST    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Public Float     $ 22.2
Entity Common Stock, Shares Outstanding   10,561,700  
Documents Incorporated by Reference

Portions of the registrant’s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K are incorporated by reference into Part III of this Annual Report on Form 10-K.

    
Security Exchange Name NASDAQ    
Entity Central Index Key 0001544227    
Amendment Flag false    
Document Fiscal Year Focus 2022    
Document Fiscal Period Focus FY    
ICFR Auditor Attestation Flag false    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Chicago, Illinois